< Back

March, 2018

TNF Inhibitors Continue to Lead In Brand Access Across Stakeholders; Orencia, Otezla, Costenyx Fall Next in Line

Knowledge Edge Brand Access Marketplace Dynamics | March 2018

TNF Inhibitors Continue to Lead In Brand Access Across Stakeholders

While stakeholders continue to consider Humira, Enbrel and Remicade as first line treatments for autoimmune diseases, slowly second-line product preferences, especially within other classes of therapy (e.g., IL-17 inhibitors and IL-23 inhibitors) are beginning to emerge.

TNF Inhibitors Continue to Lead In Brand Access Across Stakeholders; Orencia, Otezla, Costenyx Fall Next in Line

 

Download Complimentary Slide

These and other findings can be found in Health Strategies Group’s recently released research Autoimmune Market Access Stakeholder Drug Management Landscape.

Key topics included in this research:
Summary analysis

  • Capabilities assessment by stakeholder on access risks and opportunities
  • Impact analysis for biopharmaceutical companies

Current stakeholder use of general and brand-specific management tactics, including:

  • Preferred brand selection
  • Utilization management
  • Distribution management
  • Alternative payment models, financial incentives, and performance metrics

 

Visit our Brand Access Marketplace Dynamics webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.